Huntington's Disease Treatment Market Gains Momentum in North America

The global Huntington’s disease treatment market size was estimated at USD 500 million in 2024 and is projected to reach USD 1,871.2 million by 2030, growing at a CAGR of 23.8% from 2025 to 2030. Key factors driving this growth include the anticipated label expansion of Ingrezza for treating chorea associated with Huntington’s Disease (HD), the substantial burden of HD in Western countries, and the presence of a robust pipeline of disease-modifying therapies.

A study published in the Journal of the International Parkinson and Movement Disorder Society reported that the incidence of HD stands at 0.48 per thousand, with a prevalence of 4.88 per thousand—figures that have increased in recent years. This rising trend has intensified the demand for more effective and innovative treatment solutions.

HD's progressive neurological impact, along with regional differences in prevalence—higher in Europe, North America, and Australia, and lower in Asia—contributes to the rising need for treatments, especially in high-burden areas. Variations in diagnostic practices and case detection further influence this disparity, highlighting the necessity for standardized and accessible therapeutic options.

Given its hereditary nature, HD also elevates the demand for genetic counseling, early testing, and diagnostic resources. These services are crucial for individuals and families making decisions about early interventions, family planning, and participation in clinical trials. A 2022 study in Neurological India discussed the intricacies of genetic counseling and testing in HD, emphasizing challenges such as anticipation, consanguinity, and the presence of intermediate alleles. The findings underscore the importance of comprehensive counseling to support affected families in decision-making and psychological adjustment.

In the absence of a definitive cure, the market continues to seek treatments that mitigate HD symptoms and slow disease progression. Significant advancements in gene therapy and neuroprotective research are fueling optimism. Ongoing R&D efforts aim to enhance patient quality of life and eventually identify a long-term solution for the disease.

Order a free sample PDF of the Huntingtons Disease Treatment Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• North America held the largest share of the Huntington’s disease treatment market in 2024, accounting for 40.85% of global revenue.
• Asia Pacific is projected to register the fastest CAGR during the forecast period due to rising disease awareness, increased product availability, and growing prevalence in emerging economies.
• The symptomatic treatment segment represented the entire market share (100%) in 2024 and is expected to remain dominant.
• Hospital pharmacies led distribution channels in 2024, contributing over 56.00% to total market revenue.

Market Size & Forecast

• 2024 Market Size: USD 500 Million
• 2030 Projected Market Size: USD 1,871.2 Million
• CAGR (2025–2030): 23.8%
• Largest Market: North America
• Fastest Growing Market: Asia Pacific

Key Huntington’s Disease Treatment Companies

Several leading pharmaceutical firms are making significant contributions to the HD treatment landscape by developing innovative drugs and conducting advanced clinical trials. Their continued investments are critical to meeting the complex demands of this growing market segment.

Major Companies Include:

• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Hetero
• Lupin
• Hikma Pharmaceuticals PLC
• Reddy’s Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• uniQure NV
• Latus Bio

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The Huntington’s disease treatment market is witnessing robust growth, driven by an urgent need for effective therapies, advancements in gene-targeting technologies, and increasing disease prevalence across various regions. The expansion of symptomatic treatment options, strategic R&D efforts, and rising global awareness—especially in high-prevalence areas—are shaping a promising future for the market. As major players continue to innovate and collaborate, the industry is poised to deliver more accessible, precise, and life-enhancing solutions for patients and families affected by this challenging neurodegenerative disorder.